Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade.

Huemer F, Lang D, Westphal T, Gampenrieder SP, Hutarew G, Weiss L, Hackl H, Lamprecht B, Rinnerthaler G, Greil R.

J Clin Med. 2019 Jul 10;8(7). pii: E1014. doi: 10.3390/jcm8071014.

PMID:
31295966
Free Article
2.

Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.

Huemer F, Schlintl V, Hecht S, Hackl H, Melchardt T, Rinnerthaler G, Greil R, Weiss L.

Clin Colorectal Cancer. 2019 Jun;18(2):159-166.e3. doi: 10.1016/j.clcc.2019.04.003. Epub 2019 Apr 11.

3.

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

Huemer F, Melchardt T, Jansko B, Wahida A, Jilg S, Jost PJ, Klieser E, Steiger K, Magnes T, Pleyer L, Greil-Ressler S, Rass C, Greil R, Egle A.

Eur J Haematol. 2019 May;102(5):437-441. doi: 10.1111/ejh.13218. Epub 2019 Feb 28.

PMID:
30725494
4.

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group.

N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.

PMID:
30280641
5.

Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype.

Schwartz C, Romagna A, Machegger L, Weiss L, Huemer F, Fastner G, Kleindienst W, Weis S, Greil R, Winkler PA.

World Neurosurg. 2018 Dec;120:442-447. doi: 10.1016/j.wneu.2018.09.082. Epub 2018 Sep 22.

PMID:
30253992
6.

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer.

Huemer F, Rinnerthaler G, Westphal T, Hackl H, Hutarew G, Gampenrieder SP, Weiss L, Greil R.

Oncotarget. 2018 Mar 27;9(23):16512-16520. doi: 10.18632/oncotarget.24751. eCollection 2018 Mar 27.

7.

Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.

Huemer F, Weiss L, Faber V, Neureiter D, Egle A, Geissler K, Voskova D, Zebisch A, Burgstaller S, Pichler A, Stauder R, Sperr W, Lang A, Pfeilstöcker M, Machherndl-Spandl S, Stampfl M, Greil R, Pleyer L.

Wien Klin Wochenschr. 2018 Feb;130(3-4):115-125. doi: 10.1007/s00508-018-1315-2. Epub 2018 Jan 30.

8.

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).

Huemer F, Thaler J, Piringer G, Hackl H, Pleyer L, Hufnagl C, Weiss L, Greil R.

BMC Cancer. 2018 Jan 3;18(1):11. doi: 10.1186/s12885-017-3955-4.

9.

ASCO-update: gastrointestinal tumors.

Weiss L, Huemer F, Greil R.

Memo. 2017;10(4):240-243. doi: 10.1007/s12254-017-0366-9. Epub 2017 Nov 13. Review.

10.

Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.

Wöll E, Thaler J, Keil F, Gruenberger B, Hejna M, Eisterer W, Fridrik MA, Ulmer H, Trommet V, Huemer F, Weiss L, Greil R.

Anticancer Res. 2017 Oct;37(10):5553-5558.

PMID:
28982869
11.

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.

Huemer F, Dejaco M, Grabmer C, Melchardt T, Neureiter D, Mayer G, Egle A, Greil R, Weiss L.

Wien Klin Wochenschr. 2017 Feb;129(3-4):141-144. doi: 10.1007/s00508-016-1124-4.

12.

Immune checkpoint blockade in ovarian cancer.

Weiss L, Huemer F, Mlineritsch B, Greil R.

Memo. 2016;9:82-84. Epub 2016 Jun 2. Review.

13.

Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer.

Huemer F, Melchardt T, Tränkenschuh W, Neureiter D, Moser G, Magnes T, Weiss L, Schlattau A, Hufnagl C, Ricken G, Höftberger R, Greil R, Egle A.

BMC Cancer. 2015 Dec 22;15:996. doi: 10.1186/s12885-015-2020-4.

14.

Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.

Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tränkenschuh W, Schlick K, Huemer F, Deutsch A, Neumeister P, Greil R, Pichler M, Egle A.

J Natl Compr Canc Netw. 2015 Dec;13(12):1501-8.

PMID:
26656519
15.

Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?

Huemer F, Gampenrieder SP, Schlattau A, Greil R.

Clin Breast Cancer. 2014 Feb;14(1):e17-20. doi: 10.1016/j.clbc.2013.09.009. Epub 2013 Sep 28. No abstract available.

PMID:
24246725
16.

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.

Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F, Stahel R; European EGFR Workshop Group.

J Thorac Oncol. 2010 Oct;5(10):1706-13. doi: 10.1097/JTO.0b013e3181f1c8de.

Supplemental Content

Loading ...
Support Center